Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gritstone Oncology Inc (GRTS)
NASDAQ:GRTS
Holding GRTS?
Track your performance easily
GRTS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $3.33
Previous Close$0.56
Volume431.25K
Average Volume (3M)1.28M
Market Cap
$66.51M
Enterprise Value$112.86M
Total Cash (Recent Filing)$55.71M
Total Debt (Recent Filing)$102.49M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Nov 07, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding118,109,074
10 Day Avg. Volume818,950
30 Day Avg. Volume1,276,690
Standard Deviation0.52
R-Squared0.00231
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.94
Price to Sales (P/S)131.11
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue26.51
Enterprise Value/Gross Profit6.91
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$4.25Price Target Upside654.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Gritstone Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company is expected to present updated results from the Phase 2 portion of the GRANITE study later this quarter, which could be a major catalyst for the stock.
Earnings And Financial PerformanceGritstone reported 2Q results slightly ahead of consensus estimates on lower-than-anticipated expenses.
Regulatory ProgressIf the positive early trends continue to strengthen, management is expected to meet with the FDA to finalize on the design of the Phase 3 portion as well as the regulatory path forward.
Bears Say
EarningsRecent equity weakness is attributed to disappointing ctDNA primary efficacy results that overshadowed better than expected preliminary PFS dataset.
Financial PerformanceShares were trading down as much as 40% after the proposed financing announcement.
Product DevelopmentGritstone’s other programs including the CORAL COVID vaccine and the SLATE off-the-shelf cancer vaccine are currently on pause as the company seeks additional partners and/or financing options.
---
Ownership Overview
19.85% Insiders
9.57% Mutual Funds
22.03% Other Institutional Investors
48.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRTS FAQ
What was Gritstone Oncology Inc’s price range in the past 12 months?
Gritstone Oncology Inc lowest stock price was $0.42 and its highest was $3.33 in the past 12 months.
What is Gritstone Oncology Inc’s market cap?
Currently, no data Available
When is Gritstone Oncology Inc’s upcoming earnings report date?
Gritstone Oncology Inc’s upcoming earnings report date is Nov 07, 2024 which is in 51 days.
How were Gritstone Oncology Inc’s earnings last quarter?
Gritstone Oncology Inc released its earnings results on Aug 13, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.274 by $0.114.
Is Gritstone Oncology Inc overvalued?
According to Wall Street analysts Gritstone Oncology Inc’s price is currently Undervalued.
Does Gritstone Oncology Inc pay dividends?
Gritstone Oncology Inc does not currently pay dividends.
What is Gritstone Oncology Inc’s EPS estimate?
Gritstone Oncology Inc’s EPS estimate is -$0.19.
How many shares outstanding does Gritstone Oncology Inc have?
Gritstone Oncology Inc has 118,109,080 shares outstanding.
What happened to Gritstone Oncology Inc’s price movement after its last earnings report?
Gritstone Oncology Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.274. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gritstone Oncology Inc?
Among the largest hedge funds holding Gritstone Oncology Inc’s share is Versant Venture Management, LLC. It holds Gritstone Oncology Inc’s shares valued at 2M.
---
Gritstone Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.25 (654.75% Upside)
$4.25 (654.75% Upside)
Blogger Sentiment
Bullish
GRTS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.70%
12-Months-Change
Fundamentals
Return on Equity
-201.94%
Trailing 12-Months
Asset Growth
-35.97%
Trailing 12-Months
Company Description
Gritstone Oncology Inc
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
---
GRTS Company Deck
---
GRTS Earnings Call
Q1 2024
0:00 / 0:00
---
GRTS Stock 12 Month Forecast
Average Price Target
$4.25
▲(654.75% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
ADC Therapeutics
―
Black Diamond Therapeutics
―
Cellectar Biosciences
―
Best Analysts Covering GRTS
1 Year
1 Year Success Rate
6/23 ratings generated profit
1 Year Average Return
-17.07%
reiterated a buy rating last month
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -17.07% per trade.
---